STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3152 by analyst upside · 2026-08-12
MASS
908 Devices Inc.
Healthcare · Market Cap $414M · P/E 0x
ANALYST PRICE TARGET
+9.9%
implied upside to consensus target
Current Price $10.01
Consensus Target $11.0
Bull Target $12.0
Bear Target $10.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
0
Sell
0
52-Week Low $5.03
52-Week High $10.34
YTD Return +96.7%
FUNDAMENTALS
Market Cap $414M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.97
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $58M
Profit Margin -62.4%
52-WEEK RANGE
52-Week Low $5.03
52-Week High $10.34
Current Price $10.01
Bear Target $10.0
Bull Target $12.0
● Now $10.01 ● Target $11.0
TRADING DATA
Avg Volume 295K
YTD Return +96.7%
Analyst Count 3
Consensus Buy
Upside to Target +9.9%
Last Updated 2026-08-12

ANALYST SUMMARY

908 Devices Inc. (MASS) is currently trading at $10.01 with a Wall Street consensus price target of $11.0, implying potential upside of 9.9% over the next 12 months. 3 analysts currently cover MASS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $10.0.

MASS operates in the Healthcare sector with a market capitalisation of $414M. The stock is up 96.7% year-to-date and is currently trading near the upper end of its 52-week range of $5.03 – $10.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MASS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2025-08-05 29% win rate (7 calls)
Stephens & Co. reit
Overweight → Overweight 2025-01-15 Building track record
Stifel - Reiterated
Buy → Buy 2024-11-13 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2024-11-13 29% win rate (7 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2024-10-17 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
64
out of 100
Coverage depth
11/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →